Melisa Kandemir

Prof. Melisa Kandemir

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EÖEvren Özçınar
Evren Özçınar
NDNur Dikmen
Nur Dikmen
Cagdas BaranCagdas Baran
Cagdas Baran
OBOnur Buyukcakir
Onur Buyukcakir
MKMelisa Kandemir
Melisa Kandemir
LYLevent Yazicioglu
Levent Yazicioglu
Background: Thoracic endovascular aortic repair (TEVAR) has become the first-line therapy for descending aortic disease. Recent studies have demonstrated that preventive revascularization of the left subclavian artery (LSA) in zone 2 TEVAR cases reduces the risk of neurological complications. However, there is no uniform consensus on the choice of revascularization techniques. Although carotid-subclavian bypass is considered the gold standard method, in situ fenestration techniques have also shown encouraging results. This study aims to compare the carotid-LSA bypass with in situ fenestration (ISF) for LSA revascularization and to discuss our treatment approach. Methods: We conducted a retrospective review of all patients undergoing zone 2 TEVAR with in situ fenestration (ISF) or carotid-subclavian artery bypasses for LSA revascularization at our institution between February 2011 and February 2024. Preoperative patient characteristics and primary outcomes, such as operative mortality, transient ischemic attack, stroke, and spinal cord ischemia, were analyzed between the groups. Results: During the 13-year study period, 185 patients underwent TEVAR procedures. Of these, 51 patients had LSA revascularization with zone 2 TEVAR; 32 patients underwent carotid-subclavian artery bypasses, and 19 underwent in situ fenestration. The technical success rate was 100%. Statistically, there was no significant difference between the groups in terms of primary outcomes such as stroke, transient ischemic attack, spinal cord ischemia, and death (p > 0.05). Conclusions: In situ fenestration (ISF) may be an effective and feasible method for LSA revascularization. With precise patient selection and in experienced hands, ISF appears to be associated with similar perioperative outcomes and mortality rates to the carotid-subclavian bypass.

EÖEvren Özçınar
Evren Özçınar
NDNur Dikmen
Nur Dikmen
AKAhmet Kayan
Ahmet Kayan
MKMelisa Kandemir
Melisa Kandemir
MSMehmet Cahit Sarıcaoğlu
Mehmet Cahit Sarıcaoğlu
Background: This study aims to evaluate and compare the outcomes and clinical efficacy of pharmacomechanical thrombectomy (PMCT) plus catheter-directed thrombolysis (CDT) and PMCT combined with CDT and venous stenting in managing acute iliofemoral deep vein thrombosis (DVT), while also assessing the long-term safety and efficacy of these interventions. Methods: A retrospective case–control study spanning 3 years involved 112 patients presenting with acute symptomatic iliofemoral deep vein thrombosis (DVT), each with a symptom duration of less than 14 days. Patients were consecutively categorized into two groups based on individual clinical indications: PMCT + CDT vs. PMCT + CDT + venous stent. Statistical analyses were conducted to compare clinical features and outcomes between the two groups. Additionally, patients were followed up for 24 months post-treatment, during which quality of life (QoL) and severity of post-thrombotic syndrome (PTS) were analyzed. Results: In this retrospective study, we analyzed a total of 112 consecutive patients, with 63 patients undergoing PMCT + CDT and 49 patients undergoing PMCT + CDT + venous stent. Between the two groups, regarding primary outcomes at 6 months, there was no difference in the observed cumulative patency rates, standing at 82.5% for PMCT + CDT and 81.6% for PMCT + CDT + stent. Survival analyses for primary, primary-assisted, and secondary patency yielded comparable results for PMCT + CDT, with p-values of 0.74, 0.58, and 0.72, respectively. The two-year patency rate was high in both groups (85.7% for PMCT + CDT vs. 83.7% for PMCT + CDT + stent). Additionally, during the follow-up period, there were no statistically significant differences observed in the incidence of PTS or the average Villalta score between the two groups. At 24 months post-intervention, the incidence of post-thrombotic syndrome (PTS) was 11.1% in the PMCT + CDT group and 22% in the PMCT + CDT + stent group (p = 0.381). Both treatment arms of the study groups experienced bleeding complications during the thrombolysis therapy; in the PMCT + CDT group, there were three cases of gastrointestinal bleeding, compared to two cases in the PMCT + CDT + stent group (p = 0.900). Additionally, there was one intracranial hemorrhage in the PMCT + CDT group and two in the PMCT + CDT + stent group. Conclusions: Pharmacomechanical thrombectomy (PMCT) combined with catheter-directed thrombolysis (CDT) therapy has shown significant efficacy in alleviating leg symptoms and reducing the occurrence of post-thrombotic syndrome (PTS), including the incidence of moderate-to-severe PTS. On the other hand, the utilization of PMCT + CDT + stent therapy, tailored to individual patients’ clinical and venous conditions, may enhance long-term venous patency and lead to superior outcomes, including improved quality of life parameters.

MSMehmet Cahit Saricaoglu
Mehmet Cahit Saricaoglu
MKMelisa Kandemir
Melisa Kandemir
ESElif Akdemir Saricaoglu
Elif Akdemir Saricaoglu
AKALİ FUAT KARAÇUHA
ALİ FUAT KARAÇUHA
EKEzel Kadiroglu
Ezel Kadiroglu
AAAhmet Ruchan Akar
Ahmet Ruchan Akar
Background: Durable mechanical circulatory support (DMCS) infections remain a serious challenge. Ventricular assist device (VAD)-specific driveline infections (DLIs) are the most common type; however, no consensus exists on their surgical management. We aimed to define the incidence, risk factors, and microbiology of DLIs and discuss the surgical treatment modalities. Methods: We retrospectively reviewed 90 patients who underwent a left or biventricular ventricular assist device (LVAD or BiVAD) implantation with either a HeartMate 2 (Abbott), HeartWare HVAD (Medtronic), or HeartMate 3 (Abbott) in a single center between 1 March 2011 and 30 May 2023. Results: DLIs were detected in 20 (21.5%) patients during the follow-up. The mean duration of VAD support was 561.1 ± 833.2 days (1–4124 days), while it was 1277.9 ± 621.6 days in the DLI group. An extended duration of VAD support was associated with higher incidence rates of late-onset DLIs (p < 0.05). A younger age and lower plasma albumin levels were independent predictive factors for the risk of a DLI, with a hazard ratio of 9.77 (95%CI: 1.3–74.5) and 10.55 (95%CI: 1.40–79.35), respectively. The removal of the biofilm with velour and DL relocation through the rectus muscle combined with vacuum-assisted strategies (VAC) were performed in nine patients. One patient developed a recurrent infection, and another patient with a deep DLI subsequently received a heart transplant. No patient underwent a device exchange for an intractable DLI. Conclusions: Our results suggest that DLIs are common infectious complications after VAD implantation, which endanger patient autonomy, and impair their quality of life and overall survival. A DL relocation through the rectus muscles and VAC strategies have a role in controlling DLIs.

13 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EÖEvren Özçınar
Evren Özçınar
FAFatma Akça
Fatma Akça
MSMehmet Cahit Sarıcaoğlu
Mehmet Cahit Sarıcaoğlu
AHAli Ihsan Hasde
Ali Ihsan Hasde
NDNur Dikmen
Nur Dikmen
SESadik Eryilmaz
Sadik Eryilmaz
Background:Advances in stent grafts and endovascular techniques have expanded the indications for thoracic endovascular aortic repair(TEVAR) to include arch lesions.In situ needle fenestration(ISNF) has emerged as a promising technique for revascularizing supra-aortic branches. The aim of this study is to evaluate the safety and efficacy of triple in situ needle fenestration during TEVAR for aortic arch pathologies in a single-center experience. Materials and methods:A retrospective analysis was conducted on fifteen patients who underwent in situ triple fenestration TEVAR between June 2023 and March 2024.The median age of the patients was 51,33 years(±19.69) and twelve of the patients were male. All procedures were performed under general anesthesia in a hybrid operating room. Ethical approval was obtained from the institutional review board, and informed consent was received from all participants. Results: Primary technical success was achieved in all cases (15/15, 100%). The mean operation time was 197.33 minutes (range: 126–302).Two patient experienced a minor hematoma at the access site. Mortality was observed in 1 patient (6.66%) during the 30-day follow-up period. The total hospital stay averaged 7 ± 3.36 days. One patient had a transient ischemic attack, but there were no incidents of stroke or spinal cord ischemia.No procedure-related endoleak was observed during the intervention; however, 8 patients required reintervention in the descending aorta. Conclusion:ISNF may be an effective and feasible method for revascularizing arch vessels, with low rates of early mortality and stroke when performed by experienced practitioners. However, larger multicenter studies with longer follow-up are needed to confirm the durability and long-term outcomes of this technique.

1 November 2024 in Turkish Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
EÖEvren Özçınar
Evren Özçınar
NDNur Dikmen
Nur Dikmen
AKAhmet Kayan
Ahmet Kayan
MKMelisa Kandemir
Melisa Kandemir
MSMehmet Cahit Sarıcaoğlu
Mehmet Cahit Sarıcaoğlu
Objective: This study aimed to evaluate and compare the outcomes and clinical efficacy of pharmacomechanical thrombectomy (PMCT) plus catheter-directed thrombolysis (CDT) and PMCT combined with CDT and venous stenting in the management of acute iliofemoral deep vein thrombosis and assess the long-term safety and efficacy of these interventions. Methods: This retrospective case-control study involved 112 patients who presented with acute symptomatic iliofemoral deep vein thrombosis. All patients had a symptom duration of less than 14 days. Sixty-three patients underwent PMCT + CDT, while the remaining 49 underwent PMCT + CDT + venous stenting. Clinical features and outcomes were compared between the two groups. Additionally, patients were followed for 24 months after treatment, during which quality of life and severity of postthrombotic syndrome (PTS) were analyzed. Results: Survival analyses for primary, primary-assisted, and secondary patency yielded comparable results for PMCT + CDT (p=0.74, p=0.58, and p=0.72, respectively). The two-year patency rate was high in both groups (85.7% for PMCT + CDT vs. 83.7% for PMCT + CDT + venous stenting). During the follow-up, there were no statistically significant differences observed in the incidence of PTS or the average Villalta score between the two groups. At 24 months after intervention, the incidence of PTS was 11.1% in the PMCT + CDT group and 22% in the PMCT + CDT + venous stenting group (p=0.381). Conclusion: The results indicate that PMCT + CDT was effective in alleviating leg symptoms and reducing the occurrence of PTS, including the incidence of moderate-to-severe PTS. The utilization of PMCT + CDT + venous stenting therapy, tailored to individual clinical and venous conditions, may enhance long-term venous patency and lead to superior outcomes, including improved quality of life parameters.

10 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EÖEvren Özçınar
Evren Özçınar
FAFatma Akça
Fatma Akça
MSMehmet Cahit Sarıcaoğlu
Mehmet Cahit Sarıcaoğlu
AHAli Ihsan Hasde
Ali Ihsan Hasde
NDNur Dikmen
Nur Dikmen
SESadik Eryilmaz
Sadik Eryilmaz
Background: Advances in stent grafts and endovascular techniques have expanded the indications for thoracic endovascular aortic repair (TEVAR) to include arch lesions. In situ needle fenestration (ISNF) has emerged as a promising technique for revascularizing supra-aortic branches. The aim of this study is to evaluate the safety and efficacy of triple in situ needle fenestration during TEVAR for aortic arch pathologies in a single-center experience. Materials and Methods: A retrospective analysis was conducted on fifteen patients who underwent in situ triple fenestration TEVAR between June 2023 and March 2024. The median age of the patients was 51,33 years (±19.69) and twelve of the patients were male. All procedures were performed under general anesthesia in a hybrid operating room. Ethical approval was obtained from the institutional review board, and informed consent was received from all participants. Results: Primary technical success was achieved in all cases (15/15, 100%). The mean operation time was 197.33 min (range: 126–302). Two patients experienced a minor hematoma at the access site. Mortality was observed in one patient (6.66%) during the 30-day follow-up period. The total hospital stay averaged 7 ± 3.36 days. One patient had a transient ischemic attack, but there were no incidents of stroke or spinal cord ischemia. No procedure-related endoleak was observed during the intervention; however, eight patients required reintervention in the descending aorta. Conclusions: ISNF may be an effective and feasible method for revascularizing arch vessels, with low rates of early mortality and stroke when performed by experienced practitioners. However, larger multicenter studies with longer follow-up are needed to confirm the durability and long-term outcomes of this technique.